Dr. James Meehan works as a Postdoctoral Research Fellow at The University of Edinburgh. He received his B.A. (Mod.) in Neuroscience at Trinity College Dublin in 2011 and his M.Sc (Res) in Biomedical Sciences at The University of Edinburgh in 2012. He completed his Ph.D. in Molecular and Clinical Medicine (Pathology) at The University of Edinburgh in 2017. Following the completion of his Ph.D., he took up a Postdoctoral research position at Heriot-Watt University, working as part of the Implantable Microsystems for Personalised Anti-cancer Therapy (IMPACT) project. Following this, he took up a Postdoctoral position in the Institute of Genetics and Cancer at The University of Edinburgh, leading projects involved in the development and validation of novel biomarkers of response to radiotherapy and chemo-hormonal treatments. His current role within The Royal (Dick) School of Veterinary Studies and Roslin Institute focuses on investigating the cellular susceptibility of Jaagsiekte sheep retrovirus (JSRV) infection and ovine pulmonary adenocarcinoma (OPA) development.
Dr. James Meehan works as a Postdoctoral Research Fellow at The University of Edinburgh. He received his B.A. (Mod.) in Neuroscience at Trinity College Dublin in 2011 and his M.Sc (Res) in Biomedical Sciences at The University of Edinburgh in 2012. He completed his Ph.D. in Molecular and Clinical Medicine (Pathology) at The University of Edinburgh in 2017. Following the completion of his Ph.D., he took up a Postdoctoral research position at Heriot-Watt University, working as part of the Implantable Microsystems for Personalised Anti-cancer Therapy (IMPACT) project. Following this, he took up a Postdoctoral position in the Institute of Genetics and Cancer at The University of Edinburgh, leading projects involved in the development and validation of novel biomarkers of response to radiotherapy and chemo-hormonal treatments. His current role within The Royal (Dick) School of Veterinary Studies and Roslin Institute focuses on investigating the cellular susceptibility of Jaagsiekte sheep retrovirus (JSRV) infection and ovine pulmonary adenocarcinoma (OPA) development.